These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17694380)

  • 1. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
    Chorianopoulos E; Jäger D; Katus HA; Frey N
    Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
    [No Abstract]   [Full Text] [Related]  

  • 2. Home blood-pressure monitoring in patients receiving sunitinib.
    Azizi M; Chedid A; Oudard S
    N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
    Gallucci G; Tartarone A; Tocchetti CG; Bochicchio AM; Coccaro M; Capobianco A; Maurea N; Improta G; Zupa A; Aieta M
    Future Oncol; 2013 Jan; 9(1):127-33. PubMed ID: 23252570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
    Bilen MA; Zurita AJ; Ilias-Khan NA; Chen HC; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY; Tannir NM
    Oncologist; 2015 Oct; 20(10):1140-8. PubMed ID: 26306901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
    Quintyne KI; Neenan T; Casserly L; Gupta R
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24872478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 11. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
    Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
    Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
    [No Abstract]   [Full Text] [Related]  

  • 12. Sunitinib and hypothyroidism.
    Wolter P; Dumez H; Schöffski P
    N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatigue with sunitinib-induced hypothyroidism.
    Senior K
    Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
    Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
    Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
    [No Abstract]   [Full Text] [Related]  

  • 17. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible cardiomyopathy associated with sunitinib and sorafenib.
    Uraizee I; Cheng S; Moslehi J
    N Engl J Med; 2011 Oct; 365(17):1649-50. PubMed ID: 22030001
    [No Abstract]   [Full Text] [Related]  

  • 19. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe exacerbation of Crohn's disease during sunitinib treatment.
    Boers-Sonderen MJ; Mulder SF; Nagtegaal ID; Jacobs JF; Wanten GJ; Hoentjen F; van Herpen CM
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):234-6. PubMed ID: 24025975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.